Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 84487-04-7 | MDL No. : | MFCD07774108 |
Formula : | C5H4BrN3O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | YRXZIHANXVKUHP-UHFFFAOYSA-N |
M.W : | 218.01 | Pubchem ID : | 12097745 |
Synonyms : |
|
Num. heavy atoms : | 11 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 45.16 |
TPSA : | 84.73 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -6.27 cm/s |
Log Po/w (iLOGP) : | 1.11 |
Log Po/w (XLOGP3) : | 1.91 |
Log Po/w (WLOGP) : | 1.34 |
Log Po/w (MLOGP) : | -0.11 |
Log Po/w (SILICOS-IT) : | -0.73 |
Consensus Log Po/w : | 0.7 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.73 |
Solubility : | 0.404 mg/ml ; 0.00185 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.31 |
Solubility : | 0.106 mg/ml ; 0.000487 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -1.91 |
Solubility : | 2.71 mg/ml ; 0.0124 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 3.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.42 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501 | UN#: | N/A |
Hazard Statements: | H302-H312-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
60% | With acetic acid; zinc In methanol; ethanol at 0 - 20℃; for 15 h; | Step 1: To a stirred mixture of 6-bromo-3-nitro-2-pyridinamine (2.5 g, 11.47 mmol) in a mixture of glacial HOAc(10 mL), MeOH (10 mL) and EtOH (10 mL) at 0 °C was added portionwise zinc dust (3.73 g, 57.35 mmol). The mixturewas stirred at rt for 15 h. The mixture was filtered through Celite, and the filtrate was concentrated under reducedpressure. The residue was partitioned between saturated aq NaHO3 and EtOAc. The organic layer was separated andthe aqueous layer was extracted with additional EtOAc. The combined organic layers were washed with brine, separatedand dried over MgSO4, filtered, and concentrated under reduced pressure to afford 6-bromopyridine-2,3-diamine (1.30g, 60percent) as a solid that did not require further purification. 1H NMR (300 MHz, DMSO-d6) δ 6.61 (d, J = 7.7 Hz, 1H), 6.47(d, J = 7.7 Hz, 1H), 5.82 (s, 2H), 4.79 (s, 2H). LCMS (ESI) m/z 188 and 190 (M+H)+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
86% | Stage #1: With hydrogen bromide In water; acetic acid at 100℃; for 26 h; Stage #2: With sodium hydrogencarbonate In water; ethyl acetate |
To a solution of commercially available 2,6-dichloro-5- nitropyridine (20.0 g, 95.3 mmol) in ethanol (300 mL) was added aqueous ammonia (60 mL), and the mixture was stirred at room temperature for 10 hours. The resulting precipitate was filtered, washed with ethanol, and dried in vacuo to give 6-amino-2-chloro-5-nitropyridine (13. [8 G, 83 percent). THE COMPOUND] thus obtained was suspended in an acetic acid solution (130 mL) of [30percent] hydrogen bromide. The suspension was stirred at [100°C] for 26 hours, cooled to room temperature, and concentrated in vacuo. The resulting residue was extracted with ethyl acetate. The organic layer was washed with saturated aqueous sodium bicarbonate and saturated brine, dried over anhydrous magnesium sulfate, and concentrated in vacuo. The residue thus obtained [ WAS RECRYSTALLIZED FROM ETHYL ACETATE TO GIVE THE TITLE COMPOUND] (14.93 g, 86 [percent).] |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
64% | With phosphorus pentaoxide; hydrogen bromide; acetic acid In toluene | B. 6-Bromo-3-nitro-pyridin-2-ylamine. To a glass pressure vessel containing 6-methoxy-3-nitro-pyridin-2-ylamine (5.0 g, 29.5 mmol) was added 30percent hydrogen bromide/acetic acid (60 mL). The vessel was sealed, and the contents were heated to 60° C. for 24 h. The reaction mixture was cooled, and the solvent was removed in vacuo giving 6.8 g (>95percent) of crude 6-amino-5-nitro-pyridin-2-ol hydrobromide (HPLC: Rt=5.46). This material (2.0 g, 8.5 mmol) was taken up in toluene (30 mL), followed by phosphorus pentoxide (2.4 g, 17.0 mmol) and tetrabutyl ammonium bromide (3.2 g, 9.7 mmol). The mixture was heated to reflux for 4 h. The reaction mixture was cooled to 0° C., diluted with saturated NaHCO3, and extracted with ethyl acetate (3*100 mL). The combined organics were washed with water (100 mL) and dried (Na2SO4) to afford 1.18 g (64percent) of 6-bromo-3-nitro-pyridin-2-ylamine. HPLC: Rt=8.17. 1H NMR (400 MHz, DMSO-d6): 8.33 (br s, 2H), 8.32 (d, J=8.6 Hz, 1H), 6.96 (d, J=8.6 Hz, 1H). |
[ 219767-18-7 ]
6-Bromo-3-nitropyridin-2-amine hydrobromide
Similarity: 1.00
[ 84487-05-8 ]
6-Bromo-5-nitropyridin-2-amine
Similarity: 0.86
[ 1211333-10-6 ]
6-Bromo-2-nitropyridin-3-amine
Similarity: 0.85
[ 84487-15-0 ]
2-Bromo-5-nitropyridin-4-amine
Similarity: 0.84
[ 6945-68-2 ]
5-Bromo-3-nitropyridin-2-amine
Similarity: 0.82
[ 219767-18-7 ]
6-Bromo-3-nitropyridin-2-amine hydrobromide
Similarity: 1.00
[ 84487-05-8 ]
6-Bromo-5-nitropyridin-2-amine
Similarity: 0.86
[ 1211333-10-6 ]
6-Bromo-2-nitropyridin-3-amine
Similarity: 0.85
[ 84487-15-0 ]
2-Bromo-5-nitropyridin-4-amine
Similarity: 0.84
[ 6945-68-2 ]
5-Bromo-3-nitropyridin-2-amine
Similarity: 0.82
[ 219767-18-7 ]
6-Bromo-3-nitropyridin-2-amine hydrobromide
Similarity: 1.00
[ 84487-05-8 ]
6-Bromo-5-nitropyridin-2-amine
Similarity: 0.86
[ 1211333-10-6 ]
6-Bromo-2-nitropyridin-3-amine
Similarity: 0.85
[ 84487-15-0 ]
2-Bromo-5-nitropyridin-4-amine
Similarity: 0.84
[ 6945-68-2 ]
5-Bromo-3-nitropyridin-2-amine
Similarity: 0.82
[ 219767-18-7 ]
6-Bromo-3-nitropyridin-2-amine hydrobromide
Similarity: 1.00
[ 84487-05-8 ]
6-Bromo-5-nitropyridin-2-amine
Similarity: 0.86
[ 1211333-10-6 ]
6-Bromo-2-nitropyridin-3-amine
Similarity: 0.85
[ 84487-15-0 ]
2-Bromo-5-nitropyridin-4-amine
Similarity: 0.84
[ 6945-68-2 ]
5-Bromo-3-nitropyridin-2-amine
Similarity: 0.82